111 related articles for article (PubMed ID: 10389141)
1. Role of MAO A and B in neurotransmitter metabolism and behavior.
Shih JC; Chen K; Ridd MJ
Pol J Pharmacol; 1999; 51(1):25-9. PubMed ID: 10389141
[TBL] [Abstract][Full Text] [Related]
2. Forebrain-specific expression of monoamine oxidase A reduces neurotransmitter levels, restores the brain structure, and rescues aggressive behavior in monoamine oxidase A-deficient mice.
Chen K; Cases O; Rebrin I; Wu W; Gallaher TK; Seif I; Shih JC
J Biol Chem; 2007 Jan; 282(1):115-23. PubMed ID: 17090537
[TBL] [Abstract][Full Text] [Related]
3. Early postnatal inhibition of serotonin synthesis results in long-term reductions of perseverative behaviors, but not aggression, in MAO A-deficient mice.
Bortolato M; Godar SC; Tambaro S; Li FG; Devoto P; Coba MP; Chen K; Shih JC
Neuropharmacology; 2013 Dec; 75():223-32. PubMed ID: 23871843
[TBL] [Abstract][Full Text] [Related]
4. Altered gene expression in early postnatal monoamine oxidase A knockout mice.
Chen K; Kardys A; Chen Y; Flink S; Tabakoff B; Shih JC
Brain Res; 2017 Aug; 1669():18-26. PubMed ID: 28535982
[TBL] [Abstract][Full Text] [Related]
5. On the functions of monoamine oxidase, the emotions, and adaptation to stress.
Richardson JS
Int J Neurosci; 1993 May; 70(1-2):75-84. PubMed ID: 8083027
[TBL] [Abstract][Full Text] [Related]
6. MAO-A and -B gene knock-out mice exhibit distinctly different behavior.
Shih JC; Chen K
Neurobiology (Bp); 1999; 7(2):235-46. PubMed ID: 10591056
[TBL] [Abstract][Full Text] [Related]
7. Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl.
Riederer P; Konradi C; Schay V; Kienzl E; Birkmayer G; Danielczyk W; Sofic E; Youdim MB
Adv Neurol; 1987; 45():111-8. PubMed ID: 3030067
[TBL] [Abstract][Full Text] [Related]
8. Selegiline and rasagiline: twins or distant cousins?
Knudsen Gerber DS
Consult Pharm; 2011 Jan; 26(1):48-51. PubMed ID: 21224199
[TBL] [Abstract][Full Text] [Related]
9. Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months.
Elizan TS; Moros DA; Yahr MD
Arch Neurol; 1991 Jan; 48(1):31-4. PubMed ID: 1898848
[TBL] [Abstract][Full Text] [Related]
10. Selective MAO A and B inhibitors: their mechanism of action and pharmacology.
Finberg JP; Youdim MB
Neuropharmacology; 1983 Mar; 22(3 Spec No):441-6. PubMed ID: 6304562
[TBL] [Abstract][Full Text] [Related]
11. Regulation of MAO-A and MAO-B gene expression.
Shih JC; Chen K
Curr Med Chem; 2004 Aug; 11(15):1995-2005. PubMed ID: 15279563
[TBL] [Abstract][Full Text] [Related]
12. Monoamine oxidase inhibitors and the cheese effect.
Anderson MC; Hasan F; McCrodden JM; Tipton KF
Neurochem Res; 1993 Nov; 18(11):1145-9. PubMed ID: 8255365
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
Nagatsu T; Sawada M
J Neural Transm Suppl; 2006; (71):53-65. PubMed ID: 17447416
[TBL] [Abstract][Full Text] [Related]
14. Structure and mechanism of monoamine oxidase.
Edmondson DE; Mattevi A; Binda C; Li M; Hubálek F
Curr Med Chem; 2004 Aug; 11(15):1983-93. PubMed ID: 15279562
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
Marconi S; Zwingers T
Eur Rev Med Pharmacol Sci; 2014 Jul; 18(13):1879-82. PubMed ID: 25010617
[TBL] [Abstract][Full Text] [Related]
16. CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure.
Okoye AA; Picker LJ
Immunol Rev; 2013 Jul; 254(1):54-64. PubMed ID: 23772614
[TBL] [Abstract][Full Text] [Related]
17. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
Heinonen EH; Myllylä V
Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
[TBL] [Abstract][Full Text] [Related]
18. MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology.
Mallajosyula JK; Kaur D; Chinta SJ; Rajagopalan S; Rane A; Nicholls DG; Di Monte DA; Macarthur H; Andersen JK
PLoS One; 2008 Feb; 3(2):e1616. PubMed ID: 18286173
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of selegiline.
Gerlach M; Youdim MB; Riederer P
Neurology; 1996 Dec; 47(6 Suppl 3):S137-45. PubMed ID: 8959982
[TBL] [Abstract][Full Text] [Related]
20. Monoamine oxidase (MAO) activity as a determinant in human neurophysiology.
Pintar JE; Breakefield XO
Behav Genet; 1982 Feb; 12(1):53-68. PubMed ID: 6284115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
